+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using KDM6A mouse mAb (green) and negative control (red).    

  
  

The KDM6A antibody is a crucial tool in studying the KDM6A protein, a histone demethylase encoded by the *KDM6A* gene (also known as UTX). KDM6A belongs to the KDM6 subfamily of lysine demethylases and specifically removes repressive trimethyl marks from histone H3 lysine 27 (H3K27me3), a key epigenetic modification regulating gene expression. This enzyme plays vital roles in development, differentiation, and cellular identity, including X-chromosome inactivation and embryonic stem cell differentiation. Dysregulation or mutations in KDM6A are linked to cancers (e.g., T-cell acute lymphoblastic leukemia, renal cell carcinoma) and developmental disorders like Kabuki syndrome.

Antibodies targeting KDM6A enable researchers to detect its expression, localization, and interaction partners in various experimental setups, including Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP-seq). They are also used to study KDM6A’s role in chromatin remodeling, its cooperation with complexes like COMPASS or SWI/SNF, and its tumor-suppressive functions. Specificity validation is critical, as some commercial antibodies may cross-react with homologous proteins (e.g., KDM6B/UTY) or exhibit batch variability. Proper controls, such as knockout cell lines or siRNA-mediated depletion, are recommended to confirm antibody reliability. These tools continue to advance our understanding of KDM6A’s contributions to epigenetics, disease mechanisms, and potential therapeutic targeting.